Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects ≥18 to ≤55 years of age~* Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm~* Body mass index (BMI) ≥18 and ≤35 kg/sq m~* Willing and able to provide written informed consent~Exclusion Criteria:~* Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing~* Use of any investigational agent or study treatment within 30 days of Day -1~* Use of any protein or antibody-based therapeutic agents within 3 months of Screening~* Prior exposure to LX4211 or canagliflozin~* Daily use of \>5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study~* History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption~* History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying~* History of any major surgery within 6 months prior to Screening~* History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation~* History of renal disease or significantly abnormal kidney function tests~* History of hepatic disease or significantly abnormal liver function tests~* History of any active infection within 30 days prior to Day -1~* History of alcohol or substance abuse within 2 years prior to Day 1~* History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2~* Donation or loss of \>500 mL of blood or blood product within 56 days of Day -1~* positive pregnancy test at Screening or Day -1~* Positive urine screen for drugs of abuse at Screening or Day -1~* Positive breath test for alcohol at Screening or Day -1~* Inability or difficulty swallowing whole tablets~* Unable or unwilling to communicate or cooperate with the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LX4211 (Type: EXPERIMENTAL): 400 mg of LX4211
- Canagliflozin (Type: ACTIVE_COMPARATOR): 300 mg canagliflozin
- Placebo (Type: PLACEBO_COMPARATOR): LX4211 placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).